ONCOTracker and the Binding Site Collaborate to Develop sBCMA Monitoring Test

by | Sep 28, 2020 | Featured News, Myeloma News | 0 comments

ONCOTracker and The Binding Site have entered an agreement to develop and commercialize a new test that measures serum levels of the B-cell maturation antigen (sBCMA) protein to monitor people with blood cancers, including multiple myeloma.

 Serum B-cell maturation antigen (sBCMA) is the cleaved form of B-cell maturation antigen (BCMA), found at low levels in the serum of normal patients and generally elevated in patients with multiple myeloma (MM).[1] Changes in sBCMA levels have been found to correlate with a MM patient’s clinical status in response to treatment.[2][3]

The novel clinical laboratory test for measuring sBCMA, has shown promise to monitor and predict outcomes for patients with common blood-based cancers including multiple myeloma (MM) and chronic lymphocytic leukemia (CLL) and other related conditions.

Under terms of the agreement, The Binding Site Group obtains a global exclusive license to develop and commercialize a sBCMA test for multiple myeloma, CLL and additional conditions. ONCOtracker which holds patented technology regarding the testing of this biomarker for multiple myeloma patients will continue to support The Binding Site’s sBCMA research and medical affairs efforts.

In the press release James Berenson, MD, Founder and President of ONCOtracker said:

“We are thrilled to partner with The Binding Site Group, the leader in myeloma diagnostics and manufacturer of Freelite®, the diagnostic standard of care in multiple myeloma. They are the perfect collaborator to further develop and commercialize the sBCMA biomarker test and an ideal match for ONCOtracker”

 

Read Full Press Release
ONCOtracker And The Binding Site Announce a Global Diagnostic License And Collaboration On Solubilized B-cell Maturation Antigen (sBCMA), A Novel Blood-based Biomarker

References:

  1. Pj, Maglione; Hm, Ko; M, Tokuyama; G, Gyimesi; C, Soof; M, Li; E, Sanchez; H, Chen; L, Radigan (2020). “Serum B-Cell Maturation Antigen (BCMA) Levels Differentiate Primary Antibody Deficiencies”. The Journal of Allergy and Clinical Immunology. In Practice. 8 (1): 283–291.e1. doi:10.1016/j.jaip.2019.08.012. PMC 6980522. PMID 31430592.
  2. Sanchez, Eric; Li, Mingjie; Kitto, Alex; Li, Jennifer; Wang, Cathy S.; Kirk, Dylan T.; Yellin, Ori; Nichols, Cydney M.; Dreyer, Marissa P.; Ahles, Cameryn P.; Robinson, Austin (2012). “Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival”. British Journal of Haematology. 158 (6): 727–738. doi:10.1111/j.1365-2141.2012.09241.x. PMID 22804669. S2CID 30678354.
  3. Ghermezi, Michael; Li, Mingjie; Vardanyan, Suzie; Harutyunyan, Nika Manik; Gottlieb, Jillian; Berenson, Ariana; Spektor, Tanya M.; Andreu-Vieyra, Claudia; Petraki, Sophia; Sanchez, Eric; Udd, Kyle (2017). “Serum B-cell maturation antigen: a novel biomarker to predict outcomes for multiple myeloma patients”. Haematologica. 102 (4): 785–795. doi:10.3324/haematol.2016.150896. ISSN 0390-6078. PMC 5395119. PMID 28034989. 

 

Submit a Comment